BC Week In Review | Dec 1, 2017
Company News

Arcturus, Synthetic Genomics partner for RNA-based vaccines

Arcturus Therapeutics Ltd. (NASDAQ:ARCT) granted Synthetic Genomics Inc. (La Jolla, Calif.) exclusive, worldwide rights to its LUNAR lipid-mediated delivery technology to develop self-amplifying RNA-based vaccines and therapeutics for humans and animals based on Synthetic Genomics'...
BC Week In Review | Oct 27, 2017
Company News

Arcturus, JNJ to develop nucleic acids to treat HBV

Arcturus Therapeutics Inc. (San Diego, Calif.) and the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) partnered to develop and commercialize nucleic acid-based compounds to treat HBV. The companies will use Arcturus' unlocked nucleomonomer...
BC Week In Review | Oct 6, 2017
Company News

Arcturus, Alcobra merging

RNA medicines company Arcturus Therapeutics Inc. (San Diego, Calif.) will merge with Alcobra Ltd. (NASDAQ:ADHD) in a stock deal expected to close this quarter. Alcobra shareholders will own about 40% of the combined company; Arcturus...
BC Week In Review | Jan 27, 2017
Clinical News

Metadoxine ER: Ph III MEASURE data

Top-line data from the double-blind, U.S. and Israeli Phase III MEASURE trial in 283 adult patients with ADHD showed that once-daily 1,400 mg oral metadoxine ER missed the primary endpoint of improving CAARS from baseline...
BC Week In Review | Oct 17, 2016
Clinical News

Metadoxine ER: Phase III hold

FDA placed a full clinical hold on metadoxine ER to treat ADHD and fragile X syndrome, which affects the double-blind, placebo-controlled, international Phase III MEASURE trial in about 750 ADHD patients. According to Alcobra, FDA...
BioCentury | Oct 3, 2016

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
BC Extra | Sep 28, 2016
Clinical News

Alcobra's MDX on hold

Alcobra Ltd. (NASDAQ:ADHD) said FDA placed a clinical hold on the company's MDX metadoxine ER to treat ADHD and fragile X syndrome, including the Phase III MEASURE study in ADHD. According to Alcobra, FDA said...
BC Week In Review | Sep 5, 2016
Clinical News

HLD100: Phase II started

Highland began the open-label, U.S. Phase II HLD100-103 trial to evaluate 10-40 mg oral HLD100 once daily in the evening in 24 patients ages 6-12. Highland Therapeutics Inc. , Toronto, Ontario   Product: HLD100   Business:...
BC Week In Review | May 23, 2016
Company News

Neos Therapeutics sales and marketing update

Neos launched once-daily Adzenys XR-ODT amphetamine in the U.S. to treat ADHD in patients ages six and older. The wholesale acquisition cost (WAC) of a 3.1, 6.3, 9.4, 12.5, 15.7 or 18.8 mg tablet is...
BC Week In Review | Feb 1, 2016
Clinical News

Adzenys XR-ODT amphetamine regulatory update

FDA approved an NDA from Neos for Adzenys XR-ODT amphetamine to treat ADHD in patients ages >=6. Neos plans to launch the drug next quarter. The extended-release, orally disintegrating tablet formulation of amphetamine polistirex uses...
Items per page:
1 - 10 of 94